20+ full codes, 2,400+ articles translated and updated. Case law linked to every article. Read the actual text before you ask a lawyer about it — free, no login required.
20+
french codes
Fully translated
2,400+
articles in English
Updated regularly
480+
court rulings linked
Per article
Free
full access
No login required
Showing 3461–3470 of 69883 articles for “Art. I-1°-a ter”
…all inform him in writing of the reasons preventing him from being redeployed.The employer may only terminate the employment contract if he can justify either his inability to offer a job under the co…
…mstances referred to in Article L. 1226-2-1, the compensation due to the employee in respect of the termination of employment shall be paid either directly by the employer, or by means of the cover it…
…ber of the special negotiating body or a member of the European works council may only take place after authorisation from the labour inspector.
…ystem for each medicinal product or each product for which the marketing authorisation was issued after 21 July 2012; 2° Monitors the results of the risk reduction measures described in the risk manag…
For the medicinal products mentioned in 1° of II of article L. 5121-12 and in II of article L. 5121-12-1, the obligations set out in article R. 5121-161 and articles R. 5121-166 to R. 5121-170 are car…
Any company or organisation exploiting a medicinal product or a product mentioned in Article R. 5121-150 shall implement a pharmacovigilance system in order to fulfil its pharmacovigilance obligations…
…ement on the European Economic Area or a third country of which it is aware, without delay and no later than fifteen days following receipt of the information; b) Any suspected non-serious adverse rea…
…risation, as well as data concerning any use of the medicinal product that does not comply with the terms of the marketing authorisation and any information relating to the volume of sales and prescri…
…be due to the allergens he has prepared and supplied, of which he is aware, without delay and no later than fifteen days following receipt of the information; 2° Any non-serious adverse reaction susp…
The company or organisation exploiting a medicinal product or a product referred to in Article R. 5121-150 may not communicate information relating to pharmacovigilance to the general public about thi…
Avocate au Barreau de Paris
Toque #C2396
15+ Years In French Corporate Practice
English · French · Russian
Ready When You Are
A 20–30 minute call, in English, to scope the engagement. No obligation, no preliminary fee. You will leave the call with a clear view of what the work will cover and what it will cost.
20+ full codes and 2,400+ articles in English, with the key court rulings linked to every article — free to read.
Read MoreA lawyer-reviewed report explaining how the relevant articles apply to your situation, with case-law analysis and next steps.
Read MoreScope your matter with a Paris-Bar avocate — incorporation, contracts, disputes — handled bilingually, end to end.
Read More
